- Immunovant Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Immunovant Inc To Discuss Portfolio Update Call TranscriptNov 28, 2023
- Immunovant Inc Initial Phase 1 Results Call TranscriptSep 26, 2023
- Immunovant Inc Fireside Chat Hosted by LifeSci Capital TranscriptDec 08, 2022
- Immunovant Inc Investor Day TranscriptSep 28, 2022
- Immunovant Inc To Discuss On Two New Indications For Batoclimab Call TranscriptSep 07, 2022
- Q4 2022 Immunovant Inc Earnings Call TranscriptJun 08, 2022$3.92 (-8.20%)Earnings
- Immunovant Inc at UBS Global Healthcare Conference TranscriptMay 23, 2022
- Immunovant Inc To Host R&D Day (Virtual) TranscriptMar 30, 2022
- Immunovant Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Immunovant Inc To Discuss Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022 Call TranscriptJan 05, 2022
- Immunovant Inc at Stifel Healthcare Conference (Virtual) TranscriptNov 17, 2021
- Immunovant Inc at Roivant R&D Day (Virtual) TranscriptSep 28, 2021
- Q1 2022 Immunovant Inc Earnings Call TranscriptAug 09, 2021$7.78 (+0.39%)Earnings
- Q4 2021 Immunovant Inc Earnings Call TranscriptJun 01, 2021$9.4 (-37.99%)Earnings
- Immunovant, Inc. - Special Call TranscriptFeb 02, 2021
- Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 12, 2020
- Immunovant, Inc. - Special Call TranscriptAug 25, 2020
- Immunovant Inc Annual Shareholders Meeting TranscriptAug 19, 2020
- Immunovant Inc Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a Trial Of IMVT-1401 In Thyroid Eye Disease, And Provides Corporate Update TranscriptMar 30, 2020
Immunovant Inc at JPMorgan Healthcare Conference Transcript
&-
Good morning, everyone. I'm Colin Minicus associate here at JPMorgan Healthcare Group. It's my pleasure to welcome Immunovant to the 42nd Annual JPMorgan Healthcare conference. Just to recap on the format. We'll hold Q&A questions at the end. However, throughout the webcast or throughout the presentation, feel free to submit questions through the questions portal. Without further ado, please welcome CEO of Immunovant, Peter Salzmann.
Thank you, Colin, and thank you to JPMorgan for having us at this conference. Morning everyone, in the room and on the webcast. I'm really excited about this conference call and I were talking a little bit about the fireside chat format, which is great with Q&A, which I really enjoy. But the timing and format of the JPM conference allows for a little bit of looking back and looking forward, which I think is really, really valuable. I'm going to be making some forward-looking statements today, and I encourage
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)